Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation

Atherosclerosis. 2014 Sep;236(1):108-15. doi: 10.1016/j.atherosclerosis.2014.06.011. Epub 2014 Jun 28.

Abstract

Background: A number of studies have suggested that angiotensin II (AII) receptor type 1 (ATR1) blocking drugs (ARBs) have anti-inflammatory effects however the mechanisms responsible are poorly investigated.

Objective: To determine the role of extracellular signal regulated kinase (ERK)1/2 in ARB induced anti-inflammatory effects within human carotid atherosclerosis.

Methods: Atheroma samples obtained from patients undergoing carotid endarterectomy were cultured with and without ATR1 (irbesartan), ERK1/2 (PD98059), AII ([Sar(1), Ile(8)]-AII) and angiotensin converting enzyme (ACE)2 (DX600) blockade. The in vitro effects of ATR1 and ERK1/2 blockade and exogenous AII on serum stimulated healthy, primary vascular cells were also investigated. Outcome was assessed by measuring cytokine, (interleukin (IL)-6, IL-8, C-C motif chemokine (CCL)2, C-X-C motif chemokine (CXCL)5, osteoprotegerin (OPG), osteopontin (OPN), CXCL16), concentrations in supernatants and phosphorylated ERK1/2 in the tissue lysates using ELISA. ERK1/2 expression in the tissue was assessed using Western blotting.

Results: Irbesartan reduced concentrations of IL-6, IL-8, CCL2, CXCL5, OPG, OPN and CXCL16 in both atheroma and primary vascular cell culture supernatants. The reduction in cytokine levels in the atheroma supernatant was correlated to a reduction in ERK1/2 expression in the tissue. Inhibition of ERK1/2 downregulated IL-6, IL-8 and CXCL5 in both atheroma and cell culture supernatants. AII and ACE2 blockade had no impact on cytokine or active ERK1/2 levels in the atheroma culture.

Conclusion: Our findings suggest that ATR1 blockade downregulates atheroma tissue ERK1/2 expression leading to a reduction in cytokine production and that a non-AII agonist ATR1 signalling response may induce expression of these inflammation associated cytokines in the atheroma.

Keywords: Angiotensin II; Angiotensin receptor blocker; Anti-Inflammatory; Atheroma; Cytokine; Extracellular signal regulated kinase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Sarcosine-8-Isoleucine Angiotensin II / pharmacology*
  • Aged
  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Biphenyl Compounds / pharmacology*
  • Carotid Arteries / pathology
  • Cells, Cultured
  • Chemokines / metabolism
  • Cytokines / metabolism*
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / enzymology
  • Endothelium, Vascular / metabolism
  • Enzyme Activation / drug effects
  • Enzyme Induction / drug effects
  • Female
  • Humans
  • Inflammation
  • Irbesartan
  • MAP Kinase Signaling System / drug effects
  • Male
  • Middle Aged
  • Mitogen-Activated Protein Kinase 1 / genetics
  • Mitogen-Activated Protein Kinase 1 / metabolism*
  • Mitogen-Activated Protein Kinase 3 / genetics
  • Mitogen-Activated Protein Kinase 3 / metabolism*
  • Osteoprotegerin / metabolism
  • Peptides / pharmacology*
  • Plaque, Atherosclerotic / pathology
  • Renin-Angiotensin System / drug effects*
  • Renin-Angiotensin System / physiology
  • Tetrazoles / pharmacology*

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Biphenyl Compounds
  • Chemokines
  • Cytokines
  • DX600 peptide
  • Osteoprotegerin
  • Peptides
  • TNFRSF11B protein, human
  • Tetrazoles
  • 1-Sarcosine-8-Isoleucine Angiotensin II
  • MAPK1 protein, human
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Irbesartan